Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

@article{Brightling2015EfficacyAS,
  title={Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.},
  author={Christopher Brightling and Pascal Chanez and Richard Leigh and Paul M O'Byrne and Stephanie Korn and D She and Richard D May and Katie Streicher and Koustubh Ranade and Edward Piper},
  journal={The Lancet. Respiratory medicine},
  year={2015},
  volume={3 9},
  pages={
          692-701
        }
}
BACKGROUND Interleukin 13 is a central mediator of asthma. Tralokinumab is a human interleukin-13 neutralising monoclonal antibody. We aimed to assess the efficacy and safety of two dosing regimens of tralokinumab in patients with severe uncontrolled asthma. METHODS We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 2b study at 98 sites in North America, South America, Europe, and Asia. Patients aged 18-75 years with severe asthma and two to six… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 78 CITATIONS

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 24 Citations per year over the last 3 years

Similar Papers

Loading similar papers…